Clinical Experience With the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies
American Journal of Hematology - United States
doi 10.1002/ajh.25000
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 23, 2017
Authors
Publisher
Wiley